Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
J Exp Clin Cancer Res. 2021 Jan 5;40(1):8. doi: 10.1186/s13046-020-01787-5.
Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal malignancy, with an average 5-year survival rate of 9% (Siegel RL, Miller KD, Jemal A. Ca Cancer J Clin. 2019;69(1):7-34). The steady increase in mortality rate indicates limited efficacy of the conventional regimen. The heterogeneity of PDAC calls for personalized treatment in clinical practice, which requires the construction of a preclinical system for generating patient-derived models. Currently, the lack of high-quality preclinical models results in ineffective translation of novel targeted therapeutics. This review summarizes applications of commonly used models, discusses major difficulties in PDAC model construction and provides recommendations for integrating workflows for precision medicine.
胰腺导管腺癌（PDAC）是一种极其致命的恶性肿瘤，平均 5 年生存率为 9%（Siegel RL、Miller KD、Jemal A. Ca Cancer J Clin. 2019;69(1):7-34）。死亡率的稳步上升表明常规治疗方案的效果有限。PDAC 的异质性要求在临床实践中进行个性化治疗，这需要构建用于生成患者衍生模型的临床前系统。目前，缺乏高质量的临床前模型导致新型靶向治疗药物的转化效果不佳。本文综述了常用模型的应用，讨论了 PDAC 模型构建中的主要难点，并为整合精准医学工作流程提出了建议。
